Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study
Background:
Cholinesterase inhibitors are commonly used to treat dementia. These drugs enhance the effects of acetylcholine, and reports suggest they may precipitate bradycardia in some patients. We aimed to examine the association between use of cholinesterase inhibitors and hospitalization for bradycardia.
Methods and Findings:
We examined the health care records of more than 1.4 million older adults using a case-time-control design, allowing each individual to serve as his or her own control. Case patients were residents of Ontario, Canada, aged 67 y or older hospitalized for bradycardia between January 1, 2003 and March 31, 2008. Control patients (3∶1) were not hospitalized for bradycardia, and were matched to the corresponding case on age, sex, and a disease risk index. All patients had received cholinesterase inhibitor therapy in the 9 mo preceding the index hospitalization. We identified 1,009 community-dwelling older persons hospitalized for bradycardia within 9 mo of using a cholinesterase inhibitor. Of these, 161 cases informed the matched analysis of discordant pairs. Of these, 17 (11%) required a pacemaker during hospitalization, and six (4%) died prior to discharge. After adjusting for temporal changes in drug utilization, hospitalization for bradycardia was associated with recent initiation of a cholinesterase inhibitor (adjusted odds ratio [OR] 2.13, 95% confidence interval [CI] 1.29–3.51). The risk was similar among individuals with pre-existing cardiac disease (adjusted OR 2.25, 95% CI 1.18–4.28) and those receiving negative chronotropic drugs (adjusted OR 2.34, 95% CI 1.16–4.71). We found no such association when we replicated the analysis using proton pump inhibitors as a neutral exposure. Despite hospitalization for bradycardia, more than half of the patients (78 of 138 cases [57%]) who survived to discharge subsequently resumed cholinesterase inhibitor therapy.
Conclusions:
Among older patients, initiation of cholinesterase inhibitor therapy was associated with a more than doubling of the risk of hospitalization for bradycardia. Resumption of therapy following discharge was common, suggesting that the cardiovascular toxicity of cholinesterase inhibitors is underappreciated by clinicians.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study. PLoS Med 6(9): e32767. doi:10.1371/journal.pmed.1000157
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000157
Souhrn
Background:
Cholinesterase inhibitors are commonly used to treat dementia. These drugs enhance the effects of acetylcholine, and reports suggest they may precipitate bradycardia in some patients. We aimed to examine the association between use of cholinesterase inhibitors and hospitalization for bradycardia.
Methods and Findings:
We examined the health care records of more than 1.4 million older adults using a case-time-control design, allowing each individual to serve as his or her own control. Case patients were residents of Ontario, Canada, aged 67 y or older hospitalized for bradycardia between January 1, 2003 and March 31, 2008. Control patients (3∶1) were not hospitalized for bradycardia, and were matched to the corresponding case on age, sex, and a disease risk index. All patients had received cholinesterase inhibitor therapy in the 9 mo preceding the index hospitalization. We identified 1,009 community-dwelling older persons hospitalized for bradycardia within 9 mo of using a cholinesterase inhibitor. Of these, 161 cases informed the matched analysis of discordant pairs. Of these, 17 (11%) required a pacemaker during hospitalization, and six (4%) died prior to discharge. After adjusting for temporal changes in drug utilization, hospitalization for bradycardia was associated with recent initiation of a cholinesterase inhibitor (adjusted odds ratio [OR] 2.13, 95% confidence interval [CI] 1.29–3.51). The risk was similar among individuals with pre-existing cardiac disease (adjusted OR 2.25, 95% CI 1.18–4.28) and those receiving negative chronotropic drugs (adjusted OR 2.34, 95% CI 1.16–4.71). We found no such association when we replicated the analysis using proton pump inhibitors as a neutral exposure. Despite hospitalization for bradycardia, more than half of the patients (78 of 138 cases [57%]) who survived to discharge subsequently resumed cholinesterase inhibitor therapy.
Conclusions:
Among older patients, initiation of cholinesterase inhibitor therapy was associated with a more than doubling of the risk of hospitalization for bradycardia. Resumption of therapy following discharge was common, suggesting that the cardiovascular toxicity of cholinesterase inhibitors is underappreciated by clinicians.
: Please see later in the article for the Editors' Summary
Zdroje
1. QaseemA
SnowV
CrossJT,Jr
ForcieaMA
HopkinsR,Jr
2008 Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 148 370 378
2. MasudaY
2004 Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease–from basic research to bedside. Curr Alzheimer Res 1 315 321
3. Calvo-RomeroJM
Ramos-SaladoJL
1999 [Symptomatic sinus bradycardia associated with donepezil]. Revista de Neurologia 28 1070 1072
4. SuleymanT
TevfikP
AbdulkadirG
OzlemS
2006 Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J 23 641 642
5. BordierP
GarrigueS
BaroldSS
BressollesN
LanusseS
2003 Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 5 429 431
6. NewbyVJ
KennyRA
McKeithIG
2004 Donepezil and cardiac syncope: a case report. Int J Geriatr Psychiatry 19 1110 1112
7. TavassoliN
SommetA
Lapeyre-MestreM
BagheriH
MontrastrucJ
2007 Drug interactions with cholinesterase inhibitors: an analysis of the french pharmacovigilance database and a comparison of two national drug formularies. Drug Safety 30 1063 1071
8. RoisinT
Van ErmenA
RogiersA
2006 Cardiac adverse effects with cholinesterase inhibitors. Drug Safety 29 930
9. ShepherdG
Klein-SchwartzW
EdwardsR
1999 Donepezil overdose: a tenfold dosing error. Ann Pharmacother 33 812 815
10. GillSS
BronskillSE
MamdaniM
SykoraK
LiP
2004 Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 11 e274 e285
11. BordierP
GarrigueS
LanusseS
MargaineJ
RobertF
2006 Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs 20 411 417
12. MorganrothJ
GrahamS
HartmanR
AnandR
2002 Electrocardiographic effects of rivastigmine. J Clin Pharmacol 42 558 568
13. JuurlinkDN
MamdaniMM
LeeDS
KoppA
AustinPC
2004 Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 543 551
14. MamdaniM
JuurlinkDN
LeeDS
RochonPA
KoppA
2004 Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363 1751 1756
15. RayJG
MamdaniM
TsuyukiRT
AndersonDR
YeoEL
2001 Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161 1405 1410
16. LeeDS
TuJV
JuurlinkDN
AlterDA
KoDT
2005 Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 1240 1247
17. LipscombeLL
GomesT
LevesqueLE
HuxJE
JuurlinkDN
2007 Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298 2634 2643
18. JuurlinkDN
MamdaniM
KoppA
LaupacisA
RedelmeierDA
2003 Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289 1652 1658
19. MamdaniMM
TuK
van WalravenC
AustinPC
NaylorCD
2000 Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ 162 1421 1424
20. Park-WyllieLY
JuurlinkDN
KoppA
ShahBR
StukelTA
2006 Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 1352 1361
21. LevyAR
O'BrienBJ
SellorsC
GrootendorstP
WillisonD
2003 Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10 67 71
22. MaclureM
1991 The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133 144 153
23. MaclureM
MittlemanMA
2000 Should we use a case-crossover design? Annual Review of Public Health 21 193 221
24. DonnanPT
WangJ
2001 The case-crossover and case-time-control designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 10 259 262
25. SchneeweissS
SturmerT
MaclureM
1997 Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 6 (Suppl 3) S51 S59
26. SuissaS
1998 The case-time-control design: further assumptions and conditions. Epidemiology 9 441 445
27. SuissaS
1995 The case-time-control design. Epidemiology 6 248 253
28. GreenlandS
1996 Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 7 231 239
29. Canadian Institute for Health Information 2003 The International Statistical Classification of Diseases and Related Health Problems - Tenth Revision Ottawa, Canada Canadian Institute for Health Information
30. JuurlinkDN
MamdaniMM
KoppA
RedelmeierDA
2006 The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163 813 821
31. ArbogastPG
RayWA
2009 Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 18 67 80
32. ArbogastPG
KaltenbachL
DingH
RayWA
2008 Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology 19 30 37
33. RainaP
SantaguidaP
IsmailaA
PattersonC
CowanD
2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148 379 397
34. GillSS
AndersonGM
FischerHD
BellCM
LiP
2009 Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169 867 873
35. WinbladB
GauthierS
ScintoL
FeldmanH
WilcockGK
2008 Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70 2024 2035
36. US FDA 2005 Possible increased mortality in patients with mild cognitive impairment. Dear Healthcare Professional Letter: www.fda.gov/medwatch/SAFETY/2005/reminylDDLmarch.pdf
37. GreenbergHM
1984 Bradycardia at onset of sudden death: potential mechanisms. Ann N Y Acad Sci 427 241 252
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2009 Číslo 9
- Statinová intolerance
- Monoklonální protilátky v léčbě hyperlipidemií
- Pleiotropní účinky statinů na kardiovaskulární systém
- Význam hydratace při hojení ran
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
Najčítanejšie v tomto čísle
- Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines
- Grading Quality of Evidence and Strength of Recommendations: A Perspective
- The GRADE System for Rating Clinical Guidelines
- Inflammatory Markers and Outcomes in Cardiovascular Disease